Cargando…
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186646/ https://www.ncbi.nlm.nih.gov/pubmed/35702397 http://dx.doi.org/10.1016/j.ekir.2022.05.031 |
| _version_ | 1784724986094682112 |
|---|---|
| author | Rovin, Brad H. Boxhammer, Rainer Thakur, Anjali Ronco, Pierre M. |
| author_facet | Rovin, Brad H. Boxhammer, Rainer Thakur, Anjali Ronco, Pierre M. |
| author_sort | Rovin, Brad H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9186646 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91866462022-06-10 Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study Rovin, Brad H. Boxhammer, Rainer Thakur, Anjali Ronco, Pierre M. Kidney Int Rep Research Letter Elsevier 2022-06-10 /pmc/articles/PMC9186646/ /pubmed/35702397 http://dx.doi.org/10.1016/j.ekir.2022.05.031 Text en © 2022 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Research Letter Rovin, Brad H. Boxhammer, Rainer Thakur, Anjali Ronco, Pierre M. Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study |
| title | Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study |
| title_full | Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study |
| title_fullStr | Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study |
| title_full_unstemmed | Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study |
| title_short | Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study |
| title_sort | immunologic responses after covid-19 vaccination in patients with membranous nephropathy receiving anti–cd38 felzartamab therapy: results from the phase 1b/2a m-place study |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186646/ https://www.ncbi.nlm.nih.gov/pubmed/35702397 http://dx.doi.org/10.1016/j.ekir.2022.05.031 |
| work_keys_str_mv | AT rovinbradh immunologicresponsesaftercovid19vaccinationinpatientswithmembranousnephropathyreceivinganticd38felzartamabtherapyresultsfromthephase1b2amplacestudy AT boxhammerrainer immunologicresponsesaftercovid19vaccinationinpatientswithmembranousnephropathyreceivinganticd38felzartamabtherapyresultsfromthephase1b2amplacestudy AT thakuranjali immunologicresponsesaftercovid19vaccinationinpatientswithmembranousnephropathyreceivinganticd38felzartamabtherapyresultsfromthephase1b2amplacestudy AT roncopierrem immunologicresponsesaftercovid19vaccinationinpatientswithmembranousnephropathyreceivinganticd38felzartamabtherapyresultsfromthephase1b2amplacestudy |